Therapeutic application of nutraceuticals in diabetic nephropathy: Current evidence and future implications
- 16 May 2020
- journal article
- review article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 36 (8)
- https://doi.org/10.1002/dmrr.3336
Abstract
Diabetes mellitus (DM) is a common metabolic disease which may cause several complications, such as diabetic nephropathy (DN). The routine medical treatments used for DM are not effective enough and have many undesirable side effects. Moreover, the global increased prevalence of DM makes researchers try to explore potential complementary or alternative treatments. Nutraceuticals, as natural products with pharmaceutical agents, have a wide range of therapeutic properties in various pathologic conditions such as DN. However, the exact underlying mechanisms have not been fully understood. The purpose of this review is to summarize recent findings on the effect of nutraceuticals on DN.Keywords
This publication has 201 references indexed in Scilit:
- Severe Acute Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132 due to Proteasome-Independent Inhibition of M-CalpainJournal of Virology, 2012
- Inhibition of high glucose‐induced inflammatory response and macrophage infiltration by a novel curcumin derivative prevents renal injury in diabetic ratsBritish Journal of Pharmacology, 2012
- Impaired mitochondrial complex III and melatonin responsive reactive oxygen species generation in kidney mitochondria of db/db miceJournal of Pineal Research, 2011
- The Proteasome Inhibitor Velcade Enhances rather than Reduces Disease in Mouse Hepatitis Coronavirus-Infected MiceJournal of Virology, 2010
- Interplay between Akt and p38 MAPK pathways in the regulation of renal tubular cell apoptosis associated with diabetic nephropathyAmerican Journal of Physiology-Renal Physiology, 2010
- Fat and Beyond: The Diverse Biology of PPARγAnnual Review of Biochemistry, 2008
- Change in post‐translational modifications of histone H3, heat‐shock protein‐27 and MAP kinase p38 expression by curcumin in streptozotocin‐induced type I diabetic nephropathyBritish Journal of Pharmacology, 2008
- PPARγ in human and mouse physiologyBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- Resveratrol is a class IA phosphoinositide 3-kinase inhibitorBiochemical Journal, 2007
- Transcription factor-κB (NF-κB) and renal diseaseKidney International, 2001